.png)
Eyes on BMS, Pfizer, & Amgen
Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...
top of page
Eyes on Pharma
Check-out What Intel Caught our Eye
Jana Chisholm
Sep 205 min read
Eyes on BioPharma Headlines
This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait
Jana Chisholm
Aug 116 min read
Eyes On Industry News & Views
News & Views - sharing some oncology, AZD, M&A tidbits that caught our eye.
Jana Chisholm
Jun 54 min read
Eyes on Recent News from BioPharma + a 2023 Top WW 2023 List
This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.
Jana Chisholm
May 185 min read
Eyes on Pharma Restructures + Pfizer's Clinical SAE
We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..
Jana Chisholm
May 24 min read
1Q24 BioPharma Deals & Raises
We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...
Jana Chisholm
Apr 163 min read
Eyes on Corporate Restructuring
Lately we've been keeping Eyes On the corporate restructuring in the BioPharma sector. We've seen Big Pharma and BioTech refocusing ...
Jana Chisholm
Mar 244 min read
Eyes on Current Events - Deals, Approvals & Operations
We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.
Jana Chisholm
Mar 113 min read
Eyes On Healthcare Headlines
Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...
Jana Chisholm
Jan 107 min read
Eyes on Genetic Medicines & Pipelines
Following up on our previous post about Gene Therapies, we are sharing data on Genetic Medicines in development - pipelines, targets, dates
Jana Chisholm
Jan 27 min read
Eyes on Gene Therapy - The Background
We've been keeping Eyes On the Gene Therapy area - and thought we would post some general information about the area ...
Jana Chisholm
Dec 1, 20233 min read
Eyes on Clinical Trial Data, Supply Upgrades, and Patent Litigation
The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and
Jana Chisholm
Nov 24, 20233 min read
Eyes on Casgevy, Pfizer & More
Some of this week's news includes Casgevy Approval, Novo's REDEFINE 4 Trial, , new Manufacturing plant and more.
Robin Bateman
Dec 28, 20222 min read
Eyes On - Reviews & Previews for BioPharma & MedTech
I've got Eyes On the Review / Preview Articles for the Healthcare Industry. It's interesting to see a snapshot of 2022 and some predictions
Robin Bateman
Aug 18, 20226 min read
Heartburn from Zantac
This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.
jroele
Jul 20, 20221 min read
PharmaTell is in the Top 10!
We are excited to announce PharmaTech Outlook selected us as one of the Top 10 Pharma Marketing Services Companies in Europe – 2022!
Robin Bateman
Jul 10, 20222 min read
Pharma CI Europe Conference +FDA Updates + Clinical Data Readouts
The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.
Robin Bateman
May 15, 20222 min read
Product Approvals, Delays & Disappointments
This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01
Robin Bateman
May 8, 20222 min read
Quarterly Results, Biogen & Conference Planning
The PharmaTell Team has been busy curating Quarterly Results reports & upcoming conference planners + keeping up with Biogen next steps.
Robin Bateman
Apr 20, 20222 min read
AACR Updates & CAR-T Overview
This week the team has been enjoying the spring holidays and keeping their eyes on some of the recent news from AACR and learning a bit more
bottom of page